Investment Rating - The report maintains a "Buy" rating for the company, with a target price of HKD 51.00, indicating a potential upside of 59.4% from the current price of HKD 32.00 [1][6][11]. Core Insights - The company is expected to see a narrowing of losses in 2025, supported by a cash reserve of over HKD 2 billion post-IPO, which will bolster R&D and operations for the next 2-3 years. The commercialization performance of Fluorouracil after its inclusion in the medical insurance list is anticipated to drive significant sales growth in 2026 [2][6]. - The report highlights the potential of the differentiated pan-RAS pipeline, with upcoming data readouts for GFH375 in pancreatic and lung cancer expected to be promising. The next-generation RAS-targeted molecules are also anticipated to show early clinical success [2][6]. Financial Summary - The company is projected to generate revenue of RMB 1.30 billion in 2025, a 24% year-on-year increase, primarily from overseas collaboration income related to GFH375. R&D expenses are expected to decrease by 15% due to reduced licensing costs associated with Fluorouracil [6][12]. - The adjusted loss for 2025 is forecasted to narrow by 9% to RMB 227 million, with operating cash outflow decreasing by 34% to RMB 136 million. The year-end cash and bank balance is expected to exceed RMB 2 billion, providing a solid foundation for future R&D and operations [6][12]. - Revenue projections for 2026E are set at USD 85 million, with gross profit expected to be USD 33 million, maintaining a gross margin of 39.3% [6][12]. Pipeline and Catalysts - The report emphasizes several upcoming catalysts, including the completion of patient enrollment for GFH375 in Phase III trials for pancreatic cancer and the initiation of registration studies for non-small cell lung cancer (NSCLC). Additionally, the confirmation of the recommended Phase II dose (RP2D) for GFH276 and the entry of more preclinical products into IND applications are highlighted as key developments [6][12].

Investment Rating - The report maintains a "Buy" rating for the company, with a target price of HKD 51.00, indicating a potential upside of 59.4% from the current price of HKD 32.00 [1][6][11]. Core Insights - The company is expected to see a narrowing of losses in 2025, supported by a cash reserve of over HKD 2 billion post-IPO, which will bolster R&D and operations for the next 2-3 years. The commercialization performance of Fluorouracil after its inclusion in the medical insurance list is anticipated to drive significant sales growth in 2026 [2][6]. - The report highlights the potential of the differentiated pan-RAS pipeline, with upcoming data releases for GFH375 in pancreatic and lung cancer expected to be promising. The next-generation RAS-targeted molecules are also anticipated to show early clinical success [2][6]. Financial Summary - Revenue for 2025 is projected at RMB 130 million, a 24% year-on-year increase, primarily driven by overseas collaboration income related to GFH375. R&D expenses are expected to decrease by 15% due to reduced licensing costs associated with Fluorouracil [6][12]. - The adjusted loss for 2025 is expected to narrow by 9% to RMB 227 million, with operating cash outflow decreasing by 34% to RMB 136 million. The year-end cash and bank balance is projected to exceed RMB 2 billion, providing a solid foundation for future R&D and operations [6][12]. - The report provides updated revenue forecasts for 2026E at USD 85 million, with a gross profit of USD 33 million and a gross margin of 39.3%. The net loss for 2026E is projected at USD 353 million [6][12]. Pipeline and Catalysts - The report emphasizes several upcoming catalysts, including the completion of patient enrollment for GFH375 in Phase III trials for pancreatic cancer and the initiation of a registrational study for non-small cell lung cancer (NSCLC). Additionally, confirmation of the recommended Phase II dose (RP2D) for GFH276 and the entry of more preclinical products into IND applications are expected [6][12].

Group 1: WuXi Biologics (2269 HK) - Significant improvement in profit margins expected in 2025, driven by new technologies and CMO [1] - Revenue for 2025 projected at RMB 21.8 billion, a 17% year-on-year increase, with gross margin rising by 5.0 percentage points to 46.0% [1] - Free cash flow expected to grow over 70% to RMB 2.3 billion, with capital expenditures around RMB 7.1 billion [1][2] - Target price raised to HKD 35.80, maintaining a neutral rating [2] Group 2: Gensun Pharmaceuticals (2595 HK) - Revenue for 2025 expected to reach RMB 130 million, a 24% year-on-year increase, with adjusted losses narrowing by 9% to RMB 227 million [3] - Cash reserves at year-end projected to exceed RMB 2 billion, supporting R&D and operations for the next 2-3 years [3] - Anticipated significant sales growth in 2026 following the inclusion of Fluorouracil in the medical insurance directory [3] Group 3: Hesai Technology (2525 HK) - Revenue for Q4 2025 reached RMB 1 billion, a 39% year-on-year increase, with a shipment volume of 631,000 units, up 184.2% [9] - Management raised 2026 shipment guidance to 3-3.5 million units, previously set at 2-3 million [9] - 2025 GAAP net profit expected at RMB 440 million, with a non-GAAP net profit of RMB 550 million [9][10] Group 4: Xiaomi Group (1810 HK) - Q4 2025 total revenue increased by 7% year-on-year to RMB 116.9 billion, with a gross margin of 20.8% [12] - Adjusted net profit decreased by 24% to RMB 6.35 billion, facing storage cost pressures [12][13] - Continued investment in AI expected to reach RMB 16 billion in 2026, with a cumulative investment of RMB 60 billion over three years [13] Group 5: ZhongAn Online (6060 HK) - Net profit for 2025 expected to increase by over 80% to RMB 1.102 billion, with a 198.3% increase when excluding one-time impairment losses [14][15] - Health insurance premium income projected to grow by 20% annually over the next three years [15] - Target price maintained at HKD 23, corresponding to a 1.40x 2026 target P/B ratio [16] Group 6: Henderson Land Development (12 HK) - Revenue for 2025 increased by 1.9% to HKD 25.74 billion, with net profit declining by approximately 10.2% to HKD 5.65 billion [17] - Contract sales in Hong Kong expected to reach HKD 19.271 billion, a 71% year-on-year increase [17] - Target price maintained at HKD 32.68, reflecting a significant discount to net asset value [18]

Core Viewpoint - The article highlights the significant progress and potential of Jinfang Pharmaceutical in the RAS-targeted therapy market, showcasing its comprehensive pipeline and recent financial performance [2][3]. Financial Performance - For the fiscal year 2025, Jinfang Pharmaceutical reported a revenue of RMB 1.30 billion, representing a year-on-year growth of 24.4%, primarily driven by collaboration and licensing agreements with Verastem regarding GFH375 [2]. - The adjusted net loss (non-IFRS) was RMB 227 million, narrowing by 9.3% compared to the previous year, indicating improved operational efficiency [2]. - As of December 31, 2025, the company had cash reserves of RMB 2.074 billion, providing substantial support for the advancement of its pipeline [2]. Product Pipeline and Clinical Development - Jinfang Pharmaceutical has established one of the most comprehensive RAS-targeted therapy matrices globally, including commercial products like Fluorouracil and clinical-stage candidates such as GFH375 and GFH276 [3]. - The first marketed product, Fluorouracil (GFH925, brand name: Daberu®), received approval in August 2024 and was included in the national medical insurance drug list in 2025 [3]. - GFH375 entered Phase III registration clinical trials in November 2025 for the treatment of metastatic pancreatic cancer, marking it as the first KRAS G12D inhibitor undergoing single-agent registration studies globally [3]. - Clinical data for GFH375 showed an overall response rate (ORR) of 40.7% and a disease control rate (DCR) of 96.7% in pancreatic cancer patients, and an ORR of 57.7% and DCR of 88.5% in non-small cell lung cancer (NSCLC) patients, indicating its potential for best-in-class efficacy [3]. Collaborations and Future Prospects - Verastem has initiated multiple single-agent and combination therapy trials for GFH375/VS-7375, with VS-7375 receiving FDA fast track designation for treating KRAS G12D mutant metastatic pancreatic cancer [4]. - The management indicated that Verastem is optimizing dosing for Western populations to support future registration pathways, with a focus on the first-line combination therapy for GFH375, which is gaining attention overseas [5]. - GFH276's clinical trial application was approved in September 2025, with the first patient enrolled, and initial data showing no severe treatment-related adverse events, validating the pharmacokinetic and tissue distribution advantages of its differentiated molecular structure [5][6].

Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical sector [4] Core Insights - The pharmaceutical sector is experiencing a rebound due to the recognition of its importance as a pillar industry during the Two Sessions, alongside specific market events that have positively influenced certain stocks, particularly in innovative drugs and vitamin price increases [10][28] - The report emphasizes the importance of innovation and international expansion as key drivers for the pharmaceutical industry in 2026, with a focus on high-growth Q1 performance and strategic combinations of companies [10][21] - The report identifies specific companies to watch, including KJ Pharmaceuticals, Weili Zhibo-B, and others, highlighting their innovative drug pipelines and potential for growth [10][13][22] Summary by Sections 1. Newly Included Hong Kong Stock Connect Pharmaceutical Targets - The report outlines the new pharmaceutical targets included in the Hong Kong Stock Connect for March 2026, which are expected to benefit from improved liquidity and valuation [13] - Key companies include: - **InSilico Medicine**: Focused on AI drug discovery with promising clinical pipelines [13][17] - **KJ Pharmaceuticals**: Leading in CAR-T cell therapy for solid tumors [18][21] - **Weili Zhibo**: Developing multi-mechanism immunotherapy for tumors [22] 2. Pharmaceutical Market Review and Hotspot Tracking - The pharmaceutical index decreased by 2.78% from March 2 to March 6, underperforming compared to the ChiNext and CSI 300 indices [28] - The report notes that the pharmaceutical sector has been in a state of recovery, with specific stocks showing significant rebounds due to market dynamics [10][28] - The report highlights the trading volume in the pharmaceutical sector, which accounted for 3.40% of the total market turnover, below the historical average of 7.08% [47] 3. Industry Valuation and Performance - The current PE ratio for the pharmaceutical sector is 30.48X, which is below the historical average of 35.85X, indicating a relative undervaluation [46] - The report notes that the valuation premium of the pharmaceutical sector compared to the A-share market is at a low level, suggesting potential for future growth [46][48]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容引致的任何損失承擔任何責任。 GenFleet Therapeutics (Shanghai) Inc. 勁方醫藥科技（上海）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2595） 自願公告 GFH375獲得國內首個KRAS G12D抑制劑治療 非小細胞肺癌的突破性療法認定 本公告由勁方醫藥科技（上海）股份有限公司（「本公司」或「勁方」，連同其附屬公 司統稱「本集團」）自願刊發，以知會本公司股東及潛在投資者有關本集團最新業 務動態。 關於GFH375/VS-7375 GFH375為口服高活性、高選擇性小分子KRAS G12D(ON/OFF)抑制劑，通過非共 價形式結合KRAS G12D蛋白，抑制其與下游效應蛋白結合，從而在細胞中破壞 KRAS G12D對下游通路的持續活化，最終高效抑制腫瘤細胞增殖。臨床前研究 已顯示GFH375單藥對腫瘤生長的抑制效應隨用藥劑量和週期增長而提升，且在 激酶選擇性和安全性靶點測試 ...

Core Viewpoint - The company is expected to achieve a product revenue of approximately 11.9 billion yuan in 2025, maintaining a strong year-on-year growth rate of about 45% [1] - In Q4, the company achieved a product revenue of around 3.3 billion yuan, with a year-on-year increase of over 60%, validating its strong product competitiveness and commercialization system [1] - The growth is driven by the sustained performance of existing products and rapid market entry of new products, with significant contributions from non-oncology areas [1] Event Summary - On February 4, the company announced its product revenue for 2025, projecting around 11.9 billion yuan for the year and approximately 3.3 billion yuan for Q4 [1] - The Q4 revenue was influenced by the inclusion of six new drugs in the national medical insurance catalog, which led to a one-time inventory adjustment [1] Business Performance - The company has expanded its oncology pipeline to 13 products, demonstrating increasing synergy effects [2] - The successful expansion into chronic disease areas has resulted in outstanding achievements, showcasing strong growth potential across its product line [2] - Key growth drivers include products like Sintilimab, Orelabrutinib, and Lembozole, along with rapid market entry of new products such as Masitinib and Tolebrutinib [1][2] Future Outlook - The company is expected to continue leveraging its core advantages and strategic foresight to drive development across multiple disease areas, aiming to become a leading global biopharmaceutical company [2] - The company has 17 commercialized drugs, with one product under NMPA review and four new drug candidates in Phase III or critical clinical studies, alongside 15 other candidates in clinical research [2] Financial Projections - The company is projected to achieve revenues of 11.968 billion yuan, 22.804 billion yuan, and 26.572 billion yuan for the years 2025, 2026, and 2027, respectively, with net profits of 0.886 billion yuan, 6.679 billion yuan, and 8.004 billion yuan [2] - Following a significant global strategic partnership with Takeda, the company retains 40% rights in the U.S. for IBI363, which is expected to enhance its internationalization efforts [2]

Core Insights - The introduction of new pricing for lung cancer drugs, particularly the KRAS G12C inhibitors, has significantly reduced costs for patients, with prices dropping by nearly 70% for some medications [2][4][7] - The 2025 medical insurance directory includes 50 innovative drugs, with nearly half being cancer treatments, highlighting a focus on unmet clinical needs [2] - The competitive landscape for KRAS G12C inhibitors is intensifying, with companies now competing on clinical efficacy and commercial execution rather than just pricing [5][7][8] Pricing and Market Impact - The price of Fluorouracil has decreased from approximately 24,900 yuan to 5,790.4 yuan per box, resulting in a 68.87% reduction [7] - Patients previously faced annual treatment costs of 223,200 yuan, which can now be reduced to approximately 20,845.44 yuan after insurance reimbursement, saving over 200,000 yuan annually [4] - The entry of these drugs into the insurance system is expected to reshape market dynamics and increase competition among pharmaceutical companies [4][8] Competitive Landscape - The KRAS G12C inhibitors market is characterized by three main products: Fluorouracil, Goresir, and Gexoriser, all approved for similar indications, creating a "three-legged" competitive structure [6] - The market for KRAS G12C inhibitors is not overly saturated, with the mutation occurring in about 14% of non-small cell lung cancer cases, and approximately 4.3% in the Chinese population [6] - Companies are focusing on differentiating their products through clinical evidence and effective management of side effects to establish a preferred choice among doctors and patients [7][8] Future Directions - Companies are exploring combination therapies and expanding indications beyond non-small cell lung cancer to other cancers like colorectal and pancreatic cancer, which may significantly increase market potential [13] - The focus on overcoming drug resistance and enhancing efficacy through partnerships and global market strategies is seen as essential for long-term success [13] - The competitive focus is shifting towards who can provide better clinical outcomes and safety profiles, indicating a new phase in the market dynamics for KRAS G12C inhibitors [7][8]

Core Insights - The success rate of negotiations for the National Essential Medicines List reached 88% in 2025, a significant increase from 76% the previous year, marking a seven-year high [1] - A total of 114 new drugs were added to the list, including 50 innovative first-class drugs, indicating a record number both in terms of proportion and quantity [2] - Nearly 100 drugs (98) were rejected during the formal review stage, with over 60% failing to pass expert evaluation, reflecting a continuous decline in the approval rate [1][4] Group 1: Negotiation Process and Outcomes - The negotiation process has matured over the past eight years, involving self-application by pharmaceutical companies, expert evaluations, and price negotiations, resulting in 718 submissions and 535 passing the formal review [2] - The expert evaluation phase saw a pass rate of 41.48%, with 129 drugs proceeding to negotiations, of which 112 were successfully included in the National Essential Medicines List [2] - The total number of drugs in the list increased to 3,253, with 1,857 Western medicines and 1,396 traditional Chinese medicines [8] Group 2: Reasons for Rejection - The decline in approval rates for drugs in the expert evaluation phase is attributed to increased clarity in application processes and heightened competition among similar drugs [4] - Several rejected drugs included first-class innovative drugs, with reasons such as lack of significant clinical value compared to existing treatments [5] - Four main reasons for rejection were identified: lack of innovation, high prices, and insufficient clinical necessity [6] Group 3: Support for True Innovation - The focus on "true innovation" emphasizes filling clinical gaps, offering superior alternatives, and providing better cost-effectiveness [7] - Successful new entries into the list included innovative treatments for various cancers and chronic diseases, reflecting a commitment to enhancing healthcare coverage [8] - The National Healthcare Security Administration aims to maintain a dynamic adjustment of the drug list to meet evolving clinical needs [8] Group 4: Value-Based Purchasing - The negotiation process incorporates a systematic value assessment, including expert evaluations and price calculations, to ensure fair pricing [9] - Recent improvements in price calculation methods aim to enhance fairness and scientific rigor in the evaluation process [10] - The emphasis on differentiated innovation requires pharmaceutical companies to provide substantial clinical evidence to support claims of added value [11]

Core Insights - The approval rate for drugs outside the national essential drug list has reached a four-year low during the expert review phase, indicating increasing scrutiny and higher standards for innovation [1][4] - The success rate for negotiations in the upcoming 2025 national essential drug list has improved to 88%, up from 76% the previous year, marking a seven-year high [1] - A total of 114 new drugs will be added to the national essential drug list, including 50 innovative first-class drugs, reflecting a significant increase in both quantity and quality [2][8] Group 1: Approval Rates and Trends - The approval rate for drugs in the expert review phase has declined for two consecutive years, with only 41.48% of drugs passing this stage this year [2][3] - In the past three years, the number of drugs passing the formal review has increased, but the expert review approval rate has decreased from 74.2% to 47.0% [3] - Nearly 60% of drugs outside the essential list failed to pass the expert review, highlighting a trend towards stricter evaluation criteria [1][4] Group 2: Reasons for Non-Approval - Several drugs, including first-class innovative drugs, were not approved due to lack of significant clinical value compared to existing treatments [5][6] - The "Four No Changes" principle (no change in active ingredient, indication, administration route, or clinical value) has been identified as a key reason for low approval rates [6] - High prices and mismatched value with existing treatments have also contributed to the rejection of certain drugs, with examples of significant price discrepancies noted [6] Group 3: Support for True Innovation - The national healthcare authority emphasizes support for "true innovation" and "differentiated innovation," aiming to exclude drugs that do not significantly advance clinical outcomes [5][7] - Successful drugs entering the essential list share common characteristics such as filling therapeutic gaps and offering superior alternatives [7] - The overall speed and quantity of innovative drugs entering the national essential drug list have increased, addressing various medical needs including major diseases and rare conditions [8] Group 4: Value-Based Pricing and Evaluation - The negotiation process for the national essential drug list has evolved to include a more systematic and scientific value assessment, enhancing fairness and rigor in price evaluations [10] - The approach to pricing has shifted to support higher payment thresholds for drugs with greater innovation, reflecting a value-based pricing model [10][11] - The importance of robust clinical evidence in supporting claims of additional benefits for new drugs has been highlighted, particularly in competitive therapeutic areas [11][12]